Profile Response Detail

Molecular Profile KRAS mut STK11 inact mut
Therapy MLN0128 + Phenformin
Indication/Tumor Type lung adenocarcinoma
Response Type sensitive
Create By spatt
Update By tyin


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
KRAS mut STK11 inact mut lung adenocarcinoma sensitive MLN0128 + Phenformin Preclinical Actionable In a preclinical study, Sapanisertib (MLN0128) in combination with phenformin induced apoptosis and energetic stress in human lung adenocarcinoma cell lines with concurrent KRAS and STK11 (LKB1) mutations in culture, with higher levels than either therapy as a single agent (PMID: 26574479). 26574479
PubMed Id Reference Title Details
(26574479) Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers. Full reference...